Immediate Impact
4 by Nobel laureates 6 from Science/Nature 53 standout
Citing Papers
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of Dirk Müller being referenced
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy
2021
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Dirk Müller | 141 | 579 | 58 | 440 | 341 | 30 | 1.1k | |
| John Lister‐James | 105 | 921 | 173 | 352 | 237 | 44 | 1.4k | |
| Sophia Koukouraki | 196 | 305 | 416 | 253 | 251 | 39 | 1.3k | |
| G. Meyer | 25 | 477 | 128 | 278 | 293 | 28 | 964 | |
| Thomas Levin Klausen | 57 | 638 | 88 | 209 | 127 | 44 | 1.2k | |
| Karsten Beiderwellen | 44 | 945 | 152 | 199 | 173 | 35 | 1.3k | |
| Vincent Boudousq | 65 | 423 | 112 | 121 | 80 | 46 | 865 | |
| Matteo Salgarello | 28 | 261 | 109 | 397 | 260 | 65 | 975 | |
| D. Goldstein | 37 | 457 | 102 | 393 | 74 | 36 | 1.1k | |
| Vincenzo Allegri | 16 | 404 | 170 | 382 | 420 | 31 | 1.1k | |
| K. E. Britton | 76 | 329 | 227 | 155 | 99 | 56 | 996 |
All Works
Login with ORCID to disown or claim papers
Loading papers...